Hematology Xagena

Xagena Mappa
Xagena Newsletter
Medical Meeting

Search results for "Revolade"

A double-blind, multicenter, phase III study found that long-term Eltrombopag ( Promacta, Revolade ), therapy compared with placebo treatment significantly increased platelet counts, decreased bleedin ...

New data from two long-term studies ( RAISE: 197 patients and EXTEND: 144 patients ) have shown that patients with idiopathic thrombocytopenic purpura ( ITP ), treated with Eltrombopag ( Revolade ), e ...

The Food and Drug Administration ( FDA ) has approved a supplemental New Drug Application ( sNDA ) for the once-daily use of Eltrombopag in patients with severe aplastic anaemia who have had an insuff ...